



Figure S1. Optimized media supports growth of HR+ patient-derived organoid cultures. A) Brightfield images of Patient #7 PDOs (papillary carcinoma in situ) grown in published breast organoid media, modified media #1 and modified #2. B) Quantification of diameter in PDOs grown in organoid media and modified media #2 at passage 2. C) Brightfield images of Patient #27 PDOs (invasive ductal carcinoma) grown in published breast organoid media, modified media #1 and modified #2. D) Quantification of diameter in PDOs grown in published breast organoid media and modified media #2 at passage 2. Red line indicates the mean diameter of each treatment group E) Brightfield images of Patient #8 PDOs (bone metastasis) before passaging, at passage 1 and passage 2 in modified #2 or bone metastasis media. Student's T-test was used to assess significance. Scalebars: 500 μ m (A), 200 μ m (C, E)